124 related articles for article (PubMed ID: 37202226)
21. Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma.
Yanarateş A; Yazici B
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):3-8. PubMed ID: 31818695
[TBL] [Abstract][Full Text] [Related]
22. A novel analytical approach for outcome prediction in newly diagnosed NSCLC based on [
Zhang L; Xu C; Zhang X; Wang J; Jiang H; Chen J; Zhang H
Eur Radiol; 2023 Mar; 33(3):1757-1768. PubMed ID: 36222865
[TBL] [Abstract][Full Text] [Related]
23. Prognostic role of baseline
Dondi F; Albano D; Bellini P; Cerudelli E; Treglia G; Bertagna F
Clin Imaging; 2023 Feb; 94():71-78. PubMed ID: 36495848
[TBL] [Abstract][Full Text] [Related]
24. 18 F-FDG PET/CT for evaluation of metastases in nonsmall cell lung cancer on the efficacy of immunotherapy.
Feng Y; Wang P; Chen Y; Dai W
Nucl Med Commun; 2023 Oct; 44(10):900-909. PubMed ID: 37503694
[TBL] [Abstract][Full Text] [Related]
25.
Peng L; Du B; Cui Y; Luan Q; Li Y; Li X
Clin Lung Cancer; 2022 Nov; 23(7):608-619. PubMed ID: 36089482
[TBL] [Abstract][Full Text] [Related]
26. Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.
Pellegrino S; Fonti R; Mazziotti E; Piccin L; Mozzillo E; Damiano V; Matano E; De Placido S; Del Vecchio S
Ann Nucl Med; 2019 Dec; 33(12):937-944. PubMed ID: 31612416
[TBL] [Abstract][Full Text] [Related]
27. Metabolic tumor burden on postsurgical PET/CT predicts survival of patients with gastric cancer.
Sun G; Cheng C; Li X; Wang T; Yang J; Li D
Cancer Imaging; 2019 Mar; 19(1):18. PubMed ID: 30902116
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in extensive-stage small cell lung cancer].
Ding CY; Guo Z; Li YY; Li TR
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):828-834. PubMed ID: 29151289
[No Abstract] [Full Text] [Related]
29. Application of novel quantitative techniques for fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer.
Wang D; Koh ES; Descallar J; Pramana A; Vinod SK; Ho Shon I
Asia Pac J Clin Oncol; 2016 Dec; 12(4):349-358. PubMed ID: 27550522
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of 18 F-FDG PET/computed tomography metabolic parameters in predicting sarcopenia and prognosis of treatment-naive patients with non-small cell lung cancer.
Li D; Tan X; Yuan H; Yao X; Sun X; He L; Jiang L
Nucl Med Commun; 2023 Apr; 44(4):309-317. PubMed ID: 36756769
[TBL] [Abstract][Full Text] [Related]
31. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC).
Mirili C; Guney IB; Paydas S; Seydaoglu G; Kapukaya TK; Ogul A; Gokcay S; Buyuksimsek M; Yetisir AE; Karaalioglu B; Tohumcuoglu M
Int J Clin Oncol; 2019 Feb; 24(2):168-178. PubMed ID: 30109543
[TBL] [Abstract][Full Text] [Related]
33. A new PET/CT volumetric prognostic index for non-small cell lung cancer.
Zhang H; Wroblewski K; Jiang Y; Penney BC; Appelbaum D; Simon CA; Salgia R; Pu Y
Lung Cancer; 2015 Jul; 89(1):43-9. PubMed ID: 25936471
[TBL] [Abstract][Full Text] [Related]
34. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of
Ling T; Zhang L; Peng R; Yue C; Huang L
Front Immunol; 2022; 13():1014063. PubMed ID: 36466905
[TBL] [Abstract][Full Text] [Related]
36. Role of
Yuan H; Tan X; Sun X; He L; Li D; Jiang L
Jpn J Radiol; 2023 May; 41(5):521-530. PubMed ID: 36480105
[TBL] [Abstract][Full Text] [Related]
37. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
[TBL] [Abstract][Full Text] [Related]
38. Role of various semiquantitative parameters of 18F-FDG PET/CT studies for interim treatment response evaluation in non-small-cell lung cancer.
Sharma A; Mohan A; Bhalla AS; Vishnubhatla S; Pandey AK; Bal CS; Kumar R
Nucl Med Commun; 2017 Oct; 38(10):858-867. PubMed ID: 28817456
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Value of Volumetric Parameters on Staging and Posttreatment FDG PET/CT in Patients With Stage IV Non-Small Cell Lung Cancer.
Lee JW; Lee SM; Yun M; Cho A
Clin Nucl Med; 2016 May; 41(5):347-53. PubMed ID: 26825204
[TBL] [Abstract][Full Text] [Related]
40. Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer.
Kong FS; Li L; Wang W; Campbell J; Waller JL; Piert M; Gross M; Cheng M; Owen D; Stenmark M; Huang KC; Frey KA; Ten Haken RK; Lawrence TS
Radiother Oncol; 2019 Mar; 132():241-249. PubMed ID: 30389239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
